Below is Validea's guru fundamental report for INSULET CORPORATION (PODD). Of the 22 guru strategies we follow, PODD rates highest using our P/B Growth Investor model based on the published strategy ...

Below is Validea's guru fundamental report for INSULET CORP (PODD). Of the 22 guru strategies we follow, PODD rates highest using our P/B Growth Investor model based on the published strategy of ...

Insulet stock (NASDAQ: PODD) currently trades around $200 per share, about 35% lower than the levels of over $300 seen in early November 2021. In comparison, its peer – DexCom stock – is down 55% over ...

We recently compiled a list of the 12 Best Healthcare Stocks to Buy and Hold for 5 Years. Insulet Corporation is one of them. Insulet Corporation (NASDAQ:PODD) is a global leader in tubeless insulin ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Insulet (PODD) reports results for the quarter ended September 2025. While this widely-known consensus outlook is ...